Björk I, Ylinenjärvi K, Olson S T, Bock P E
Department of Veterinary Medical Chemistry, Swedish University of Agricultural Sciences, Uppsala Biomedical Center.
J Biol Chem. 1992 Jan 25;267(3):1976-82.
A synthetic tetradecapeptide having the sequence of the region of the antithrombin chain amino-terminal to the reactive bond, i.e. comprising residues P1 to P14, was shown to form a tight equimolar complex with antithrombin. A similar complex has previously been demonstrated between alpha 1-proteinase inhibitor and the analogous peptide of this inhibitor (Schulze, A. J., Baumann, U., Knof, S., Jaeger, E., Huber, R. and Laurell, C.-B. (1990) Eur. J. Biochem. 194, 51-56). The antithrombin-peptide complex had a conformation similar to that of reactive bond-cleaved antithrombin and, like the cleaved inhibitor, also had a higher conformational stability and lower heparin affinity than intact antithrombin. These properties suggest that the peptide bound to intact antithrombin at the same site that the P1 to P14 segment of the inhibitor occupies in reactive-bond-cleaved antithrombin, i.e. was incorporated as a sixth strand in the middle of the major beta-sheet, the A sheet. The extent of complex formation was reduced in the presence of heparin with high affinity for antithrombin, which is consistent with heparin binding and peptide incorporation being linked. Antithrombin in the complex with the tetradecapeptide had lost its ability to inactivate thrombin, but the reactive bond of the inhibitor was cleaved as in a normal substrate. These observations suggest a model, analogous to that proposed for alpha 1-proteinase inhibitor (Engh, R.A., Wright, H.T., and Huber, R. (1990) Protein Eng. 3, 469-477) for the structure of intact antithrombin, in which the A sheet contains only five strands and the P1 to P14 segment of the chain forms part of an exposed loop of the protein. The results further support a reaction model for serpins in which partial insertion of this loop into the A sheet is required for trapping of a proteinase in a stable complex, and complete insertion is responsible for the conformational change accompanying cleavage of the reactive bond of the inhibitor.
一种合成的十四肽,其序列为抗凝血酶链中活性键氨基末端区域的序列,即包含P1至P14残基,已显示与抗凝血酶形成紧密的等摩尔复合物。先前已证明α1-蛋白酶抑制剂与其类似肽之间存在类似的复合物(舒尔茨,A.J.,鲍曼,U.,克诺夫,S.,耶格尔,E.,胡贝尔,R.和劳雷尔,C.-B.(1990年)《欧洲生物化学杂志》194,51-56)。抗凝血酶-肽复合物的构象与活性键裂解的抗凝血酶相似,并且与裂解的抑制剂一样,其构象稳定性更高,肝素亲和力比完整的抗凝血酶更低。这些特性表明,与完整抗凝血酶结合的肽与抑制剂的P1至P14片段在活性键裂解的抗凝血酶中占据的位点相同,即在主要β折叠(A折叠)中间作为第六条链并入。在与抗凝血酶具有高亲和力的肝素存在下,复合物形成程度降低,这与肝素结合和肽并入相关一致。与十四肽形成复合物的抗凝血酶失去了使凝血酶失活的能力,但抑制剂的活性键像在正常底物中一样被裂解。这些观察结果提出了一个类似于为α1-蛋白酶抑制剂提出的模型(恩格,R.A.,赖特,H.T.和胡贝尔,R.(1990年)《蛋白质工程》3,469-477),用于完整抗凝血酶的结构,其中A折叠仅包含五条链,链的P1至P14片段形成蛋白质暴露环的一部分。结果进一步支持了丝氨酸蛋白酶抑制剂的反应模型,其中该环部分插入A折叠是将蛋白酶捕获在稳定复合物中所必需的,而完全插入则导致抑制剂活性键裂解伴随的构象变化。